Rep. April McClain Delaney Sells Off Labcorp Holdings Inc. (NYSE:LH) Stock

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of Labcorp Holdings Inc. (NYSE:LH). In a filing disclosed on September 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Labcorp stock on August 6th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of Wabtec (NYSE:WAB) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Viking (NYSE:VIK) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Trimble (NASDAQ:TRMB) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Transdigm Group (NYSE:TDG) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Tractor Supply (NASDAQ:TSCO) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Middleby (NASDAQ:MIDD) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Teledyne Technologies (NYSE:TDY) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of STERIS (NYSE:STE) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Somnigroup International (NYSE:SGI) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Signet Jewelers (NYSE:SIG) on 8/25/2026.

Labcorp Trading Up 1.4%

LH traded up $4.40 during midday trading on Friday, hitting $311.36. 809,927 shares of the company were exchanged, compared to its average volume of 635,612. Labcorp Holdings Inc. has a 1-year low of $244.52 and a 1-year high of $341.80. The company has a quick ratio of 1.53, a current ratio of 1.80 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $25.25 billion, a P/E ratio of 25.75, a P/E/G ratio of 1.74 and a beta of 0.88. The firm’s 50 day moving average price is $310.39 and its 200-day moving average price is $281.94.

Labcorp (NYSE:LH) last posted its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The company had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.71 billion. During the same period in the previous year, the firm earned $4.35 earnings per share. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. As a group, equities analysts forecast that Labcorp Holdings Inc. will post 18.32 EPS for the current fiscal year.

Labcorp Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 28th were issued a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, August 28th. This represents a $2.88 annualized dividend and a yield of 0.9%. Labcorp’s payout ratio is presently 23.82%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on LH shares. Bank of America raised their price target on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a report on Monday, July 13th. JPMorgan Chase & Co. upped their price objective on shares of Labcorp from $330.00 to $360.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Truist Financial increased their price objective on shares of Labcorp from $320.00 to $350.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Morgan Stanley lifted their target price on shares of Labcorp from $308.00 to $338.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Piper Sandler boosted their target price on shares of Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $336.36.

Insider Buying and Selling

In related news, CEO Adam Schechter sold 4,669 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total value of $1,495,807.53. Following the transaction, the chief executive officer directly owned 102,565 shares in the company, valued at $32,858,749.05. This trade represents a 4.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy Summy sold 924 shares of Labcorp stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total transaction of $283,427.76. Following the transaction, the executive vice president owned 6,956 shares of the company’s stock, valued at $2,133,683.44. This represents a 11.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 8,919 shares of company stock worth $2,826,593 over the last quarter. Corporate insiders own 0.84% of the company’s stock.

Institutional Investors Weigh In On Labcorp

A number of large investors have recently bought and sold shares of LH. REAP Financial Group LLC raised its holdings in shares of Labcorp by 20.4% during the fourth quarter. REAP Financial Group LLC now owns 218 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 37 shares during the period. V Square Quantitative Management LLC grew its stake in shares of Labcorp by 1.7% in the 1st quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company’s stock valued at $645,000 after buying an additional 40 shares during the period. Hilltop Holdings Inc. boosted its holdings in Labcorp by 2.6% in the fourth quarter. Hilltop Holdings Inc. now owns 1,631 shares of the medical research company’s stock worth $409,000 after acquiring an additional 41 shares in the last quarter. Pinnacle Associates Ltd. increased its holdings in shares of Labcorp by 3.9% during the fourth quarter. Pinnacle Associates Ltd. now owns 1,126 shares of the medical research company’s stock valued at $282,000 after acquiring an additional 42 shares in the last quarter. Finally, Larson Financial Group LLC raised its position in shares of Labcorp by 37.5% during the third quarter. Larson Financial Group LLC now owns 154 shares of the medical research company’s stock worth $44,000 after purchasing an additional 42 shares during the period. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp reaffirmed its 2026 guidance of adjusted EPS of $18.10 to $18.55, broadly consistent with the analyst consensus of $18.32. Maintaining guidance supports confidence in near-term earnings visibility. Labcorp Holdings Reiterates 2026 Outlook, Issues Long-Term Guidance
• Positive Sentiment: The company issued a 2029 outlook calling for compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. The targets imply sustained expansion beyond the current year and could support a higher long-term earnings outlook. Labcorp 2026 Investor Day Announcement
• Positive Sentiment: Labcorp plans to use artificial intelligence, specialty testing, scientific capabilities and global scale to drive growth. Management also emphasized strong cash-flow generation and disciplined capital deployment, which may improve shareholder returns if execution meets expectations. Labcorp Bets Big on AI and Specialty Testing
• Neutral Sentiment: The Investor Day transcript provided additional detail on Labcorp’s strategic priorities and long-term financial framework, but the benefits depend on successful implementation and investment in new technologies and testing capabilities. Labcorp Analyst and Investor Day Transcript
• Negative Sentiment: LH recently declined about 4.3% and underperformed peers, indicating that investors may have viewed the Investor Day information as insufficient to justify the stock’s elevated valuation or may have taken profits despite the favorable long-term targets. Labcorp Stock Heads Into the Open After a 4.3 Percent Slide

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About Labcorp

Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.